Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
61.2.9874.8761
Address
Suite 301 55 Lime Street Sydney, New South Wales (NSW) 2000
Description
CardieX Ltd. engages in the provision of designing, manufacturing, and marketing medical devices used in cardiovascular health management. It operates through the following geographical segments: Americas, Europe, and Asia Pacific. The Americas segment includes pharmaceutical trials business. The Europe segment focuses on the Middle East and Africa. The Asia Pacific segment is involved in the operations of Asia, Australia, and New Zealand. The company was founded by Ross Harricks, Niall Charles Edgar Cairns, Craig R. Cooper, and Michael Francis O'Rourke in 1994 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.04 - 0.17
Trade Value (12mth)
AU$5,392.00
1 week
0%
1 month
2.56%
YTD
-58.68%
1 year
-37.06%
All time high
7.64
EPS 3 yr Growth
-36.50%
EBITDA Margin
-57.90%
Operating Cashflow
-$8m
Free Cash Flow Return
-359.30%
ROIC
-314.80%
Interest Coverage
-5.30
Quick Ratio
1.00
Shares on Issue (Fully Dilluted)
303m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
02 July 25 |
Appendix 3Y x3
×
Appendix 3Y x3 |
27 June 25 |
Application for quotation of securities - CDX
×
Application for quotation of securities - CDX |
24 June 25 |
Results of Entitlement Offer
×
Results of Entitlement Offer |
18 June 25 |
Entitlement Offer Closing & Deadline for Applications
×
Entitlement Offer Closing & Deadline for Applications |
13 June 25 |
Cardiex Investor Webinar Presentation
×
Cardiex Investor Webinar Presentation |
10 June 25 |
Cardiex Investor Webinar
×
Cardiex Investor Webinar |
06 June 25 |
Offer Booklet - Non-Renounceable Entitlement Offer
×
Offer Booklet - Non-Renounceable Entitlement Offer |
06 June 25 |
Despatch of Entitlement Offer Booklet
×
Despatch of Entitlement Offer Booklet |
06 June 25 |
Entitlement Offer Letter to Ineligible Shareholders
×
Entitlement Offer Letter to Ineligible Shareholders |
05 June 25 |
Application for quotation of securities - CDX
×
Application for quotation of securities - CDX |
05 June 25 |
Cleansing Notice
×
Cleansing Notice |
04 June 25 |
Cardiex Successfully Completes Institutional Placement
×
Cardiex Successfully Completes Institutional Placement |
02 June 25 |
Cardiex Receives TGA Approval for CONNEQT Pulse Device
×
Cardiex Receives TGA Approval for CONNEQT Pulse Device |
30 May 25 |
Cardiex Completes Placement & Launches Entitlement Offer
×
Cardiex Completes Placement & Launches Entitlement Offer |
30 May 25 |
Proposed issue of securities - CDX
×
Proposed issue of securities - CDX |
30 May 25 |
Cleansing Notice
×
Cleansing Notice |
30 May 25 |
CDX May Investor Presentation
×
CDX May Investor Presentation |
28 May 25 |
Trading Halt
×
Trading Halt |
15 May 25 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
14 May 25 |
Application for quotation of securities - CDX
×
Application for quotation of securities - CDX |
14 May 25 |
Notification regarding unquoted securities - CDX
×
Notification regarding unquoted securities - CDX |
14 May 25 |
Appendix 3Y x3
×
Appendix 3Y x3 |
09 May 25 |
Results of May 2025 Extraordinary General Meeting
×
Results of May 2025 Extraordinary General Meeting |
06 May 25 |
Lodgement of CONNEQT Pulse Device with the TGA
×
Lodgement of CONNEQT Pulse Device with the TGA |
30 April 25 |
March Quarterly Appendix 4C
×
March Quarterly Appendix 4C |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.